The canonical profile remains the primary reading view. Read the canonical profile.
We moved this profile to the current DailyMed label (SPL version 10, published September 21, 2026), which adds a separate warning about allergic reactions, and added the October 23, 2026 Drugs@FDA approval of a further generic teriparatide application. The previous version, citing label version 9, remains available. 16
What this version reported
A large randomized, placebo-controlled trial described in the label found fewer new spine fractures than placebo. The label states that teriparatide caused osteosarcoma in rats; an increased risk has not been observed in human observational studies.↗
Reader guide in this version
Key takeaway
Teriparatide is a lab-made version of the first 34 amino acids of human parathyroid hormone. It was first approved in the United States as Eli Lilly’s Forteo in 2002.1,2 It is FDA-approved for postmenopausal women with osteoporosis at high risk of fracture, to increase bone mass in men with primary or hypogonadal osteoporosis, and for osteoporosis linked to long-term glucocorticoid use.1 In the label’s main trial of 1,637 postmenopausal women, new spine fractures occurred in 5% of the teriparatide group and 14.3% of the placebo group.1 The current label adds a separate warning about allergic reactions, including anaphylaxis, angioedema and hives, reported with parathyroid hormone analogues including teriparatide.1
At a glance
- What it is
- Parathyroid hormone (1-34). The label states that teriparatide binds the same receptors as natural parathyroid hormone, with the same effects on bone and kidney.1
- FDA status
- FDA-approved. Drugs@FDA lists Forteo with an original approval date of November 26, 2002, and later teriparatide applications, the most recent approved on October 23, 2026. The cited label has no boxed warning.1,2,3,4,5,6
- Human evidence
- Large randomized trials described in the label, including a placebo-controlled fracture trial in postmenopausal women.1
- Evidence strength
- Large randomized human trials
What is teriparatide?
Teriparatide is a lab-made peptide identical to the first 34 amino acids of human parathyroid hormone, the body’s main regulator of calcium and phosphate. The label states that it is made by chemical synthesis.1
Drugs@FDA lists Forteo, from Eli Lilly, approved in 2002, and later teriparatide applications including Bonsity (2019), generic applications approved in 2023 and 2026, and a further application approved in 2024. The label cited on this page is a generic teriparatide label rather than the Forteo label.1,2,3,4,5,6
How does teriparatide work?
The label states that teriparatide binds the same receptors as natural parathyroid hormone, with the same affinity and the same effects on bone and kidney.1
The label states that teriparatide stimulates new bone formation by favoring bone-building cells over bone-removing cells.1
What do human studies show?
The label describes a double-blind, placebo-controlled trial in 1,637 postmenopausal women with osteoporosis, most of whom already had a spine fracture. New spine fractures occurred in 5% of the teriparatide group and 14.3% of the placebo group, a relative reduction of 65%.1
In a placebo-controlled trial in 437 men with primary or hypogonadal osteoporosis, spine bone density increased by an average of 5.9% with teriparatide and 0.5% with placebo, according to the label.1
The label also describes an 18-month randomized trial in 428 people with osteoporosis linked to glucocorticoid use.1
What the evidence base contains
- Controlled human trial A double-blind, placebo-controlled trial in 1,637 postmenopausal women with osteoporosis, with new spine fractures as the main outcome and a median exposure of 19 months.1
- Controlled human trial A double-blind, placebo-controlled trial in 437 men with primary or hypogonadal osteoporosis that measured spine bone density.1
- Large randomized human trial An 18-month randomized, double-blind, active-controlled trial in 428 people with osteoporosis linked to glucocorticoid use.1
Evidence-strength label: Large randomized human trials. How this label is assigned
Is teriparatide FDA-approved?
Yes. Drugs@FDA lists Forteo, application NDA021318, with an original approval date of November 26, 2002, Bonsity on October 4, 2019, a generic application (ANDA211097) on November 16, 2023, a further application (NDA218771) on June 4, 2024 and another generic application (ANDA214412) on October 23, 2026.2,3,4,5,6
The generic teriparatide label cited here (DailyMed SPL version 10, published September 21, 2026) states that it is indicated for postmenopausal women with osteoporosis at high risk for fracture, to increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture, and for men and women with osteoporosis associated with sustained glucocorticoid therapy at high risk for fracture.1
The label has no boxed warning. It states that teriparatide is contraindicated in people with a history of severe allergic reactions to it or its inactive ingredients, and that such reactions have included anaphylaxis and angioedema.1
Version 10 adds a separate warning on hypersensitivity reactions: the label states that anaphylaxis, angioedema and urticaria (hives) have been reported in people treated with parathyroid hormone analogues, including teriparatide.1
Its other warnings cover a risk of osteosarcoma based on rat studies, high blood calcium and calcium deposits in the skin, kidney stones, a fall in blood pressure on standing, and digoxin toxicity.1
Timeline
- FDA approves Forteo, according to Drugs@FDA.2
- FDA approves Bonsity, according to Drugs@FDA.3
- FDA approves a generic teriparatide application, according to Drugs@FDA.4
- DailyMed publishes the teriparatide label version cited on this page, which adds a separate warning about allergic reactions.1
- FDA approves another generic teriparatide application (ANDA214412), according to Drugs@FDA.6
What is still unknown?
Whether teriparatide causes osteosarcoma in humans: the label notes cases reported after approval but no increased risk in observational studies, and limited data beyond 2 years.1
Whether it reduces fractures in men: the label’s trial in men measured bone density.1
How often allergic reactions occur: the label lists them among reactions reported after approval, whose frequency it states cannot always be reliably estimated.1
Sources for this version
- 1Teriparatide injection, solution · SPL version 10 · published 2026-09-21 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 2Drugs@FDA application NDA021318 · original submission status AP · 2002-11-26 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 3Drugs@FDA application NDA211939 · original submission status AP · 2019-10-04 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 4Drugs@FDA application ANDA211097 · original submission status AP · 2023-11-16 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 5Drugs@FDA application NDA218771 · original submission status AP · 2024-06-04 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 6Drugs@FDA application ANDA214412 · original submission status AP · 2026-10-23 · dataset 2026-11-13 ↗
Drugs@FDA via openFDA · Official source · Source checked November 15, 2026